IP Library › Granted Patent US 11,739,087
Granted Patent B2
US 11,739,087 · App. 17/239,045 · Granted Aug 29, 2023

Inhibiting (α-v)(β-6) integrin

Inventors: Bryce A. Harrison (Framingham, MA); James E. Dowling (Lexington, MA); Matthew G. Bursavich (Needham, MA); Dawn M. Troast (Bedford, MA); Blaise S. Lippa (Newton, MA); Bruce N. Rogers (Belmont, MA); Kristopher N. Hahn (Medford, MA); Cheng Zhong (Belmont, MA); Qi Qiao (Natick, MA); Fu-Yang Lin (Sudbury, MA); Brian Sosa (Cambridge, MA); Aleksey I. Gerasyuto (Flemington, NJ); Andrea Bortolato (Metuchen, NJ); Mats A. Svensson (New York, NY); Eugene Hickey (Danbury, CT); Kyle D. Konze (Brooklyn, NY); Tyler Day (New York, NY); Byungchan Kim (West New York, NJ)
Assignee: Morphic Therapeutic, Inc.
C07D471/04A61K9/0053
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,739,087
App. No.
17/239,045
Granted
Aug 29, 2023
Kind
B2
Abstract

Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.

Claims (18)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , having the formula:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , having the formula:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , having the formula:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , having the formula:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , having the formula:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , having the formula:

pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , having the formula:

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , having the formula:

or a pharmaceutically acceptable salt thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2022
From: HARRISON, BRYCE A.; DOWLING, JAMES E.; BURSAVICH, MATTHEW G.; TROAST, DAWN M.; LIPPA, BLAISE S.; ROGERS, BRUCE N.; HAHN, KRISTOPHER N.; ZHONG, CHENG; QIAO, QI; LIN, FU-YANG; SOSA, BRIAN
To: MORPHIC THERAPEUTIC, INC.
Reel/Frame 060898/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2022
From: GERASYUTO, ALEKSEY I.; BORTOLATO, ANDREA; SVENSSON, MATS A.; HICKEY, EUGENE; KONZE, KYLE D.; DAY, TYLER; KIM, BYUNGCHAN
To: SCHRÖDINGER, INC.
Reel/Frame 060898/0036 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2022
From: SCHRÖDINGER, INC.
To: SCHRÖDINGER, LLC
Reel/Frame 060898/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2022
From: SCHRÖDINGER, LLC
To: MORPHIC THERAPEUTIC, INC.
Reel/Frame 060898/0077 →
Continuity (5)
Continuation 17001086 · Aug 24, 2020
Continuation 16555589 · Aug 29, 2019
Provisional Application 62859457 · Jun 10, 2019
Provisional Application 62724423 · Aug 29, 2018
Related Publication 20220073511A1 · Mar 10, 2022
Cited By (4)
US 12,415,796 US 12,459,942 US 12,528,803 US 12,552,786